Maveron leads $9M seed round in Kin Health to put patients back at the center of their care
The biggest opportunity in healthcare is letting doctors and patients actually talk.
For the last decade, we’ve watched healthcare innovation flow almost entirely in one direction: toward the provider. Billing, documentation, and clinical decision-making have all been rebuilt while the patient side of the exam room looks the same as it did decades ago. One billion physician appointments take place every year and patients walk out of every single one without a true record of what was said. The sickest people in our system are the ones we ask to do the most: absorb critical information in the hardest moments, manage prescriptions, follow complicated advice across visits, the list goes on.
That’s why we at Maveron have led a $9 million seed round in Kin Health, a free app that records the doctor-patient conversation and translates it into a plain-language summary patients can understand and act on. Over time, those summaries build into a longitudinal health record grounded in the only source that really counts: what their doctors actually told them.
When we look at a consumer health company at this stage, a few things stand out when we see them: founders who have lived the problem from inside the system, a product that earns the trust of the providers who gate it, and a go-to-market motion that can’t be replicated by anyone with an API key. Kin is the rare seed-stage company that brings all three. Arpan and Amit Parikh are brothers and practicing physicians who have spent their careers inside the exam room and carry the trust of the providers. Kyle Alwyn built and sold a category-defining consumer health company, HeyDoctor, to GoodRx. Doug Hirsch and Trevor Bezdek, GoodRx’s co-founders, are part of the Kin family as founding partners and executive chairmen, bringing with them the playbook for a winning consumer health business that changes lives without ever asking patients to pay.
The GoodRx parallel was important to us for several reasons. GoodRx proved, on the back of a single product and largely from the outside of the system, that consumers would adopt a free tool at scale if doctors trusted it enough to recommend it. Kin is the next iteration of that thesis, applied earlier in the care journey, with a deep physician network baked in from day one and a broad product area to grow into. In an era when AI has made it easier than ever to ship a product but no easier to build one people love (let alone one providers trust) that combination of expert credibility, distribution, and inspiration from a proven playbook is the kind of edge we think will separate this team from the rest in the category.
Kin is starting with the appointment, but the appointment is the front door to nearly every downstream decision a patient will make: the referrals they accept, the labs they complete, the prescriptions they fill, the second opinions they search for. Patients generate a billion appointments a year and walk away with nothing — no record, no continuity, no context for the next visit. The patient side of healthcare is the largest unbuilt consumer surface in the system, and Kin is the world-class team to give patients clarity, confidence, and control in the moments that matter most.